In Vitro Diagnostics (IVD)

In Vitro Diagnostics (IVDs) are essential to modern healthcare, providing data that guides diagnosis, treatment decisions, and ongoing patient management.

From centralized laboratory testing to rapid point-of-care diagnostics, IVDs operate at the intersection of medical devices, clinical science, and data and are one of the most highly scrutinized product categories in global regulatory systems.

What Are IVDs?

In Vitro Diagnostic devices are medical devices used to examine specimens derived from the human body, like blood, urine, or tissue, to provide information about a patient’s health. They are used to detect diseases or conditions, monitor health status or disease progression, and inform treatment decisions.

Common Examples of IVDs

IVDs span a wide range of technologies and applications, including blood glucose monitoring systems, infectious disease tests (e.g., COVID-19, influenza), PCR-based molecular diagnostics, immunoassays, and companion diagnostics (linked to specific drug therapies).

Key Distinction

Unlike therapeutic medical devices, IVDs do not act directly on the body. Instead, they generate clinical information that healthcare providers use to make medical decisions, thus placing a high regulatory emphasis on accuracy, reliability, and clinical relevance.

Global Regulatory Landscape

IVDs are regulated under medical device frameworks, with additional requirements specific to diagnostic performance and clinical evidence.

Key regulatory systems include the European Union’s In Vitro Diagnostic Regulation (IVDR) EU 2017/746, the United States FDA device framework, including evolving oversight of Laboratory Developed Tests (LDTs), Health Canada Medical Device Regulations, and China National Medical Products Administration (NMPA).

Across jurisdictions, regulatory expectations are increasing for clinical evidence, classification, and post-market oversight.

Risk Classification (Core Concept)

Risk classification determines the level of regulatory control applied to an IVD. Under the EU IVDR, devices are categorized into four classes:

Class A: Low individual and public health risk

Class B: Moderate risk

Class C: High individual risk and/or moderate public health risk

Class D: Highest risk (e.g., tests for life-threatening or highly transmissible diseases)

As risk classification is increased, so do clinical evidence requirements, notified body involvement, and regulatory scrutiny.

Performance Evaluation (Critical Requirement)

IVDs must demonstrate performance through a structured evaluation framework consisting of three core elements.

Scientific Validity. Establish the relationship between the analyte and the clinical condition.

Analytical Performance. Evaluation of accuracy, precision, sensitivity, specificity, and reproducibility.

Clinical Performance. Confirm that the test performs as intended in the target patient population.

Together, these elements form the foundation of IVD regulatory approval and are analogous to clinical evidence requirements in drug and device regulation.

Quality Management Systems

IVD manufacturers are expected to implement robust quality systems aligned with ISO 13485 (Quality Management Systems), ISO 14971 (Risk Management), and software lifecycle standards (for digital and AI-enabled diagnostics).

Key IVD QMS elements include design and development controls, supplier and process controls, validation and verification activities, and documentation and traceability.

Post-Market Surveillance

Regulatory oversight extends across the full product lifecycle. Manufacturers must implement systems for complaint handling and investigation, trend analysis and signal detection, vigilance and adverse event reporting, and post-market performance follow-up (PMPF).

There is an increasing emphasis on real-world performance data to confirm continued safety and effectiveness.

Key Regulatory Trends

The IVD regulatory environment is evolving rapidly, with several major trends like the expansion and enforcement of EU IVDR requirements, increased scrutiny of Laboratory Developed Tests (LDTs), increased integration of companion diagnostics with drugs and devices, and a growth in companion diagnostics and drug-device integration.

And, most recently, trends have included an integration of artificial intelligence and machine learning, and a greater focus on clinical evidence and lifecycle data.

Bottom Line

IVDs are uniquely positioned at the convergence of medical devices, clinical evidence, and data-driven healthcare. Regulatory expectations are increasing globally, particularly in risk classification, clinical and performance evidence, and lifecycle and post-market oversight.

Organizations that proactively align with global regulatory frameworks are better positioned to accelerate market access, reduce compliance risk, and maintain long-term product viability.